Welcome to
US Medical Affairs
Hematology
Welcome to
US Medical Affairs
Hematology
Start Exploring
CONGRESS LIBRARY
Browse through scientific meetings
and presentations
PUBLICATIONS
Stay informed on recent peer-reviewed
publications
CLINICAL TRIALS
Explore our clinical trials database
CONTINUING EDUCATION
Explore Accredited Continuing Education
Events
RESOURCES
Explore guidelines, medical associations,
patient advocacy groups pertaining to
Hemophilia A
PRODUCT INFORMATION
Access the US FDA-Approved label for
our medication
ASKMED BY BAYER
Connect with Bayer’s Virtual Assistant or
a Medical Science Liaison
Welcome to Bayer's Medical Affairs Hematology Platform!
For over 30 years, Bayer has been a leader in the development of therapies designed to help people with Hemophilia A all over the world.
Bayer introduced its first recombinant Factor VIII product in 1993 and has continued to innovate, developing four generations of products so far.
For over 30 years, Bayer has been a leader in the development of therapies designed to help people with Hemophilia A all over the world. Bayer introduced its first recombinant Factor VIII product in 1993 and has continued to innovate, developing four generations of products so far.
Bayer remains committed to advancing the care of people with hemophilia A through spreading awareness, as well as ongoing clinical research and real-world evidence generation. We invite you to explore educational resources and information on this website.
Follow Us
